The role of LDL-bound apoJ in the development of atherosclerosis

Q Medicine

Clinical Lipidology Pub Date : 2015-08-01 DOI:10.2217/clp.15.21

A. Rull, J. Ordóñez‐Llanos, J. L. Sánchez-Quesada

引用次数: 4

Abstract

Abstract Aggregation of LDL is considered the initial key event in atherogenesis and apoJ is an extracellular chaperone part of the quality control system against protein aggregation. A minor fraction of apoJ in blood is transported by LDL, but its role is poorly understood. Considering both the importance of LDL aggregation in atherosclerosis and the modulatory role of apoJ on protein aggregation, the function of apoJ bound to LDL could be relevant. Recent studies have shown that apoJ prevents the LDL aggregation and inhibits the cytotoxic potential of modified LDL. Other studies have reported increased content of apoJ in atherogenic LDL fractions. These observations point to apoJ as a key modulator of LDL atherogenicity.

查看原文本刊更多论文

低密度脂蛋白结合apoJ在动脉粥样硬化发生中的作用

LDL的聚集被认为是动脉粥样硬化发生的初始关键事件，apoJ是细胞外伴侣，是防止蛋白质聚集的质量控制系统的一部分。血液中载脂蛋白j的一小部分通过LDL运输，但其作用尚不清楚。考虑到LDL聚集在动脉粥样硬化中的重要性以及apoJ对蛋白质聚集的调节作用，apoJ与LDL结合的功能可能是相关的。最近的研究表明，apoJ可以阻止LDL聚集并抑制修饰LDL的细胞毒性潜能。其他研究报道了致动脉粥样硬化LDL组分中apoJ含量的增加。这些观察结果表明apoJ是LDL动脉粥样硬化的关键调节剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.